Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 5/20 | 0.43 |
| ▸ | CDK8 | P49336 | 5/20 | 0.43 |
| ▸ | CCNC | P24863 | 4/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344944 | 0.84 | TRPA1 (0.56) | TRPA1CREBBPKDM5BBRD4AR | |
| SCHEMBL17547042 | 0.82 | TRPA1 (0.54) | TRPA1CREBBPKDM5BBRD4AR | |
| SCHEMBL20132641 | 0.80 | TRPA1 (0.55) | TRPA1CREBBPKDM5BBRD4AR | |
| SCHEMBL15341806 | 0.79 | KDM5B (0.53) | TRPA1CREBBPKDM5BBRD4AR | |
| SCHEMBL15340929 | 0.76 | KDM5B (0.46) | TRPA1KDM5BARAPP | |
| SCHEMBL15334010 | 0.76 | TRPA1 (0.56) | TRPA1CREBBPKDM5BBRD4AR | |
| SCHEMBL27446328 | 0.74 | BRD4 (0.52) | CREBBPKDM5BBRD4 | |
| SCHEMBL18015720 | 0.72 | TRPA1 (0.61) | TRPA1CREBBPBRD4ARCDK8 | |
| SCHEMBL30549500 | 0.72 | TRPA1 (0.64) | TRPA1CREBBPBRD4ARCDK8 | |
| Hydrochloric Acid SCHEMBL30549506 | 0.70 | TRPA1 (0.63) | TRPA1CREBBPBRD4ARCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TRPA1 4316/4885CREBBP 401/4885KDM5B 3695/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | TRPA1 4766/4885CREBBP 942/4885KDM5B 4421/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TRPA1 4316/4885CREBBP 401/4885KDM5B 3695/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TRPA1 4316/4885CREBBP 401/4885KDM5B 3695/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | TRPA1 4766/4885CREBBP 942/4885KDM5B 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.